Evidence map›Paper›PMID 32594198›Full record

ArticleSkeletal radiology2021

Metastasizing chondroblastoma: a rare bone tumor no longer supported by the WHO classification.

Daniel Baumhoer, Dorothee Harder, Baptiste Ameline, Heather Dawson, Attila Kollar

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Skeletal radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Benign tumors of the chest wall.Journal of thoracic disease · 2024
    Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Daniel Baumhoer *Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, University of Basel, Schoenbeinstrasse 40, 4031, Basel, Switzerland. daniel.baumhoer@usb.ch.
Dorothee Harder *Department of Radiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Baptiste AmelineBone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, University of Basel, Schoenbeinstrasse 40, 4031, Basel, Switzerland.
Heather DawsonInstitute of Pathology, University of Bern, Bern, Switzerland.
Attila KollarDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
University Hospital of Basel · CHUniversity of Bern · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the World Health Organization (WHO) classification, tumors showing hematogenous spread in less than 2% of cases are categorized as "rarely metastasizing" and constitute a group of neoplasms of intermediate malignancy. Since its introduction in 2002, chondroblastoma has been considered one of the prototypic examples of this category of lesions. In the fifth and only recently published edition of the WHO classification of bone and soft tissue tumors, however, chondroblastoma was re-classified from rarely metastasizing to benign due to the rarity of cases with systemic spread. Here, we present a remarkable case of a 54-year-old male who presented with an expansile tumor in his left acromion that was diagnosed as chondroblastoma following biopsy. Three years later a local recurrence was noted during routine follow-up and a bone scan detected hypermetabolic lesions in a rib and the thoracic spine. Over time, he developed multifocal skeletal spread as well as soft tissue and pulmonary metastases, which histologically all revealed conventional chondroblastoma morphology and the highly specific H3-3B point mutation (p.Lys36Met). Thirteen years after initial diagnosis he is currently treated with experimental immunotherapy and shows stable but disseminated disease. Our case highlights that although metastasizing chondroblastoma is rare, potential systemic spread should be kept in mind in patients with chondroblastoma despite the new WHO classification.

Indexed as

Bone NeoplasmsChondroblastomaSoft Tissue NeoplasmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalWorld Health OrganizationBiologic behaviorIntermediate malignancyMetastasizing chondroblastomaWHO classification

Identifiers

PMID32594198
OpenAlexW3038014278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.